CSBio

We're looking for a passionate content writer to join our team part-time! If you LOVE peptides and have a journalistic flair, this might be the perfect opportunity for you. The ideal candidate will be a graduate student or postdoc in the peptide space, with a strong pulse on the latest developments. You'll need to craft content that resonates with both academic researchers and industry professionals, covering everything from peptide research and chemistry to manufacturing and industry news. If peptides are your passion and you can engage a diverse audience, we'd love to hear from you! Contact us at instrument@csbio.com to apply.

🌟 Exciting times at EPS 2024 in Florence, Italy! 🌟 It was an absolute pleasure to catch up with our good friends Ashraf Brik, John Wade, Fernando Albericio, Beatriz de laTorre, and Phil Dawson at the conference. A shoutout to Dario Slavazza and Dirk Kusch, who are representing CSBio with excellence and enjoying the time in Florence. We also want to extend our early congratulations to Phil Dawson on being selected to receive the American Peptide Society 2025 Bruce Merrifield Award. This honor recognizes his lifetime achievement as a peptide scientist—a testament to his significant contributions to the field. We're looking forward to seeing everyone at APS2025 in San Diego! #whothinksthatsteakistoorare #EPS2024 #Peptides #CSBio #BruceMerrifieldAward #APS2025

We're excited to announce our next article, discussing many of the current peptide therapeutics currently available on the market. 💪 The remarkable thing is that this marks the very beginning of a new era of small molecule therapeutics, especially as we continue to see any number of clinical trials investigating various other areas of interest in disease-research. Which is why we are so proud to be investigating our novel therapeutic AMTX-100, which will be a significant breakthrough in the use of peptides to treat immune-related diseases. Learn more in our next article! #peptides #inflammation #industrytrends #medicine

🚀 Exciting News in the Peptide Space! 🚀 See the latest updates in the peptide industry for the second quarter of 2024! Our newest blog post covers key news, including: 1. Novartis & Peptidream: $180M investment to develop targeted cancer radiotherapy. 2. Eli Lilly and Company: $140M deal to expand innovative cancer therapies. 3. Dandelion Health: New data library for GLP-1 drugs. 4. The University of Kansas Cancer Center: $1.4M grant for prostate cancer peptide therapy. 5. Eli Lilly and Company Tirzepatide: Positive sleep apnea trial results. 6. Entera Bio Ltd. Bio: Phase 1 data for hypoparathyroidism peptide tablets. 7. Darling Ingredients: Collagen peptides for health benefits. 8. TREOS BIO LIMITED: Phase 2 trial results for colorectal cancer treatment. 9. Metsera: $290M raised for obesity therapies. 10. Secarna Pharmaceuticals & Orbital Therapeutics: Collaboration on peptide-conjugated therapeutics. 11. NeuroBo Pharmaceuticals, Inc.: Phase 1 trial for obesity drug. 12. Viking Therapeutics, Inc.: Promising weight loss pill results. 13. Donaldson & PolyPeptide Group: Sustainable peptide manufacturing. 14. UW's Baker Lab: AI in drug peptide development. 15. Peptide Noodles: Advancements in tissue engineering. And many more! 🔗 Read the summary here: [https://lnkd.in/gBTG3-gY Stay informed with the latest insights in the peptide landscape. And if you're in the US, have a happy and safe July 4th weekend! 🇺🇸 #PeptideResearch #Biotechnology #Pharmaceuticals #Innovation

📢Event Recap: Peptide Synthesis Lunch and Learn at Stanford University📢 We are thrilled to share about our recent Peptide Synthesis Lunch and Learn event hosted at Stanford University! 🌲 🌟 🔬 Event Highlights: - Multiple labs from Stanford University Department of Chemistry and Stanford University School of Medicine were represented, fostering a dynamic exchange of ideas and collaboration. - Attendees had the opportunity to receive personalized peptide synthesis consultation from our co-founder, Dario Slavazza, who has over 30 years of peptide synthesis experience in R&D and cGMP environments. - Wesley Greiner shared some of the newest developments in research scale synthesis methodologies and advancements in green chemistry. - Engaging discussions on how the SPPS process differs once research is scaled up to gram and kilogram batches for process development and manufacturing. This event was a fantastic platform for knowledge sharing and networking, enhancing our collective understanding of peptide synthesis. A big thank you to all the attendees for making this event memorable and productive! Stay tuned for more such events as we continue to explore and innovate in the field of peptide chemistry! 🧬 If you are interested in having CSBio Instrumentation host a lunch and learn at your institution, don't hesitate to reach out! #StanfordUniversity #PeptideSynthesis #GreenChemistry #ResearchInnovation #Collaboration #ChemistryCommunity #MedicalResearch #ScienceEvents #SPPS #APS

🌱 Embracing a Greener Future in Peptide Synthesis 🌱 Exciting developments in Green Solid-Phase Peptide Synthesis (SPPS) are paving the way for more sustainable practices in peptide production! CSBio's peptide synthesizers are supporting the groundbreaking research and development in this area. 🔬 One standout and recent publication involves Novo Nordisk's use of the CSBio CS936 peptide synthesizer, which focuses on enhancing the environmental sustainability of SPPS. This research employs advanced spectrophotometric techniques to detect residual piperidine, enabling real-time monitoring and significantly reducing solvent use. This not only improves safety but also aligns with green chemistry principles by minimizing environmental impact. 💡 Other impactful studies involve the University of Bologna (Alma Mater Studiorum – Università di Bologna) and Fresenius Kabi with CSBio's CS136X peptide synthesizer, and another by Bachem, Novo Nordisk, and Fernando Albericio utilizing the CSBio CS536X peptide synthesizer where they have made strides in developing greener solvent alternatives. This research not only advances green chemistry but also showcases the flexibility and precision of CSBio synthesizers in handling green SPPS chemistries. Dive into this detailed case study that exemplifies the practical benefits of Green SPPS and discover more about how CSBio's peptide synthesizers are supporting the production of peptides for today, and the green SPPS of tomorrow. 🌍 🔗 Read the full article on CSBio's blog here [https://lnkd.in/gtQkAJNs] #GreenChemistry #PeptideSynthesis #Sustainability #Innovation #CSBio #NovoNordisk #Bachem #GreenSPPS

Are you a chemistry / biochemistry student? Are you keen to work on new techniques for the synthesis of complex oligonucleotides or peptides? Then apply for this exciting opportunity in an amazing team! https://lnkd.in/dJ2EeD-4

New posting in Discovery Process Chemistry at Spring House, PA -Exciting opportunity to join an exceptionally talented group of chemists advancing our innovative pipeline! https://lnkd.in/eDAmupPm

Remembering warmer times in sunny Scottsdale, Arizona meeting with friends and colleagues of the American Peptide Society at APS 2023! ☀ 🌵 We were thrilled to support some of the research that was presented during the poster session from the Lam Lab within UC Davis School of Medicine titled: "Comparison of Microwave and Conduction Heating for Solid Phase Peptide Synthesis" 🚀 Don't miss out on the insights that could revolutionize your approach to peptide synthesis! Check out the poster here: https://lnkd.in/gdXvkvTg

🔥 March 2024: Shaping the Future with Peptide Innovations 🔥 March 2024 marked a transformative period in the realm of peptide science, underscored by it's economic impacts, substantial investments, and a shifting landscape in healthcare delivery. Key highlights of this dynamic month include: 1. Orbis Medicines' breakthrough with €26M funding for new oral peptide therapies. 2. The projection by Goldman Sachs of GLP-1 drugs as key drivers of economic growth. 3. WuXi AppTec navigating the complexities of US-China biopharma tensions. 4. Novo Nordisk's strides in sustainable peptide synthesis through green chemistry. 5. CordenPharma's expansion enhancing peptide manufacturing for clinical development. 6. Computational advancements in cyclic peptide design for Keap1 inhibition. 7. Novel synthetic peptides targeting disease-related nucleic acids. 8. The fusion of machine learning and DFT for creating antioxidant peptides. 9. The development of innovative, temperature-sensitive fibrils for drug delivery. 10. Curve Therapeutics' securing of £40.5M from Pfizer, spotlighting peptide drug discovery. Get the summary here [https://lnkd.in/g53UNxAQ] and dive deeper into each of these pioneering stories.